Designing and delivering teleradiology services which meet your specific requirements is our forte. Our Board Certified radiologists offer preliminary, final and subspecialty reports 24/7/365. Turnaround times are set to match your needs. Our technical support center provides state of the art PACS/RIS and communication technology, which securely integrates with your current Information Systems.


Teleconsult pathologists offer services ranging from remote reporting of cyto- and histological cases, to lab design and quality assurance programs. We support the most basic lab set ups with second opinions and on-line consultations, and connect more advanced labs to our web based telepathology platform for routine reporting of diverse cases.


Our telemicrobiology services are offered by Dutch and UK Board Certified clinical microbiologists with sub-specialties in the fields of general microbiology, bacteriology, virology, parasitology, mycology, molecular diagnostics and epidemiology. Our clinical microbiologists are mainly active in clinical hospital settings, keeping them closely connected and in tune with daily clinical situations and challenges. This creates affinity with remote cases and ensures the up-to-date knowledge our customers require.

Locum Placement

Our recruitment division recruits certified radiologists, pathologists and micro biologists for part time and full time positions. In our 15 year history we successfully recruited and placed medical specialists in over 60 hospitals and clinics across the globe

Screening & Trials

From its worldwide network of Board Certified medical specialists, TeleConsult creates subspecialty teams for specific screening and clinical trial assignments. In 2012 TeleConsult’s dedicated breast radiologists were selected by the Dutch Breast Cancer Screening program to interpret its screening mammography studies.

We are hiring

We recruit, select and place sub-specialty, EU educated and certified radiologists, pathologists and microbiologists for short and long term positions. Our reputation has been built on a foundation of providing highly skilled doctors and the following core values: Professionalism, Value for money, Quality, Reliability and Integrity. Interested in joining our team? Register now!

Specialist care at your fingertips

Whether you are a hospital  department, diagnostic center or laboratory, Teleconsult doctors and IT experts bring optimal efficiency to your  workflow. A thorough analysis of your current situation, needs and requirements results in a balanced work flow management plan.

Teleconsult does not have any volume requirement and you are in full control to decide when to outsource studies to a Teleconsult doctor. To find out how your clinic or department will benefit from working with Teleconsult Europe, please contact us.


  • Balance on- and off site tasks




About Teleconsult

Founded in 2007 by Dutch radiologists, TeleConsult Europe (TCE) offers radiology services to hospitals, clinics, diagnostic centers, laboratories, medical services companies and the Dutch Government.

TCE’s mission is to provide its customers with tailored telemedicine solutions. Since its inception, TCE carefully listened to wishes and needs of its clients. This resulted in an array of interchangeable services providing radiology and pathology departments with high quality, cost efficient, flexible on- and off-site solutions.

Today TCE’s solutions consist of a combination of an on-site physician workforce, teleradiology, telepathology, and IT services. Our Western Board certified radiologists and pathologists perform reading services for a broad array of institutions varying from a 24/7 emergency reading service for hospitals and clinics, to screening services for the famous Dutch Breast Cancer Screening Program.

The primary objective of our highly trained physicians and staff is to enable our clients to provide optimal patient care and diagnostic services by placing quality and value first. Our synergetic modules provide tailored services to hospitals, clinics and imaging centers at any location on the globe. Whether you need an on-site physician, reports through telemedicine or a combination of both, we help you to realize an optimal and cost efficient workflow.

Prostate cancer - University of York scientists discover why some tumours are resistant to radiotherapy

Scientists at the University of York believe they have identified how some tiny regulatory molecules in cells can make prostate cancers resistant to radiotherapy.

It is hoped that this new development could pave the way for more effective treatments - allowing a lower dose of radiotherapy to be used while prolonging the lives of thousands of men.

Prostate cancer is the most commonly diagnosed form of male cancer in the UK and kills more than 11,000 men every year.

In the latest studies, published in European Urology and the British Journal of Cancer, scientists in The YCR Cancer Research Unit in the Department of Biology at York have shown a direct link between these tiny molecules - known as micro-RNAs - and resistance to radiotherapy.

Every cell has hundreds of micro-RNAs, whose function is to control the expression of genes.

Once regarded as "junk" by scientists, they are now considered vital for the organisation of the various tissues in the body, instructing genes when and where to be active.

The York team have now shown that they are the switch which enables cells to react very rapidly to changes in their environment, such as that provided by cancer treatments.

Previous research has revealed that all prostate cancers contain at least four different cell types, including the cancer stem cells which resist most current treatments.

By looking at the micro-RNAs present in each of the cell types individually, the researchers found that some micro-RNAs acted in a positive manner, switching off genes which could make the stem cells susceptible to radiotherapy, whilst other micro-RNAs were not expressed in the resistant stem cells, permitting the expression of resistance genes.

By manipulating the levels of these critical micro-RNAs in the clinic, scientists say it should be possible to kill greater numbers of cancer stem cells than ever before, reducing the 30 per cent of prostate cancer patients whose tumours recur after radiotherapy.

Professor Norman Maitland, of The YCR Cancer Research Unit, said prostate cancer is diagnosed in about 42,000 men every year in the UK. Of those men about a third will get radiotherapy, and of those, about a third will fail on radiotherapy.

"Doctors don't know which patients are going to relapse - and the reason they relapse is probably because the radiotherapy is not focussed on the stem cell, it is focused on the whole tumour.

"We think that by exploiting this new knowledge we can make radiotherapy more effective. What is the impact? We believe it could extend the lifetime of these men. It could also allow a lower dose of radiotherapy to be used and that's really what we are testing at the moment.

"Now we have a handle on why stem cells cause men to relapse after radiotherapy, this will be the bridge to transforming that into a treatment and making radiotherapy better."

The research used tissues from prostate cancer patients, generously donated for this purpose via a Hull-York Medical School cooperation with Mr Matt Simms at Castle Hill Hospital in Hull.

The analysis was carried out by Dr Jayant Rane, as part of an EU-funded international consortium (PRONEST), in collaboration with Professor Tapio Visakorpi (University of Tampere, Finland), and Finnish bioinformaticians Antti Ylipaa and Professor Matti Nykter.

Powered By | Full Text RSS Feed

Proposed 2016 Medicare physician cuts threaten access to community-based radiation therapy

The American Society for Radiation Oncology (ASTRO) is concerned about proposed additional payment cuts to radiation therapy detailed in the Centers for Medicare and Medicaid Services' (CMS) proposed Medicare Physician Fee Schedule (MPFS), released July 8, 2015, which will take effect on January 1, 2016. Freestanding centers estimate that the combined impact of the Medicare proposals would result in a five to seven percent reduction in payment for radiation oncology services at community-based centers, although the cuts will vary and could be more than 10 percent for some freestanding centers, depending upon their patient population.

The proposed CY 2016 MPFS includes several significant adjustments for radiation oncology care. The proposed changes include setting reimbursement values for newly created treatment codes for conventional radiation therapy techniques and intensity modulated radiation therapy; increasing the assumed equipment utilization rates for radiation treatment delivery, which has the effect of reducing reimbursement for cancer treatment; and removing from the direct practice expense formula the costs associated with important equipment, most notably on-board imaging, which is critical to ensuring safe and accurate radiation treatments. ASTRO represents radiation oncology physicians practicing in hospitals and community-based clinics and will submit comments and recommendations in a letter to CMS by September 8, 2015.

"The implementation of these three dramatic policy changes at once represents too much, too fast for community-based clinics to absorb and could have devastating effects, particularly for those centers in rural and underserved areas. ASTRO and its members are very concerned that the cumulative impact of recent significant cuts, totalling about 25 percent during the past six years, plus these new reductions could seriously threaten access to care for many cancer patients by potentially forcing clinics to close or limit their services," said ASTRO Chair Bruce G. Haffty, MD, FASTRO.

Preliminary data from ASTRO's approximately two-week survey, from July 9 through July 20, of the almost 1,400 community-based radiation therapy centers in the U.S. indicates that with reimbursement cuts of five to 10 percent, nearly 30 percent of the practices indicated they may have to close their doors; approximately 62 percent may have to consolidate practice locations; and an estimated 41 percent of practices may be forced to discontinue accepting patients covered by Medicare.

"ASTRO is asking Congress and CMS to work with radiation oncology stakeholders to significantly scale back the proposed changes to the equipment utilization rate assumption and to restore inclusion of the direct practice expenses involving image guidance. We look forward to working closely with policymakers to protect patient access to safe and high-quality radiation therapy throughout the country," concluded Haffty.

Powered By | Full Text RSS Feed

Researchers develop first genetic test to predict tumor sensitivity to radiation therapy

Powered By | Full Text RSS Feed